Compare Salesforce Inc (CRM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Sanofi SA — how do they compare? Salesforce Inc trades at $229.13 (market cap $187.48B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Salesforce Inc is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Sanofi SA for 94 Days on average.
| CRM | SNY | |
|---|---|---|
Market Cap | $187.48B | $95.18B |
Volume | 6,155,822 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $266.23 | $52.34 |
52-Week Low | $150.12 | $39.51 |
Typical Hold Time | 89 Days | 94 Days |
Enterprise Value | $217.82B | $114.48B |
Dividend Yield | 0.77% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $227.80, up 1.44% today, but remains under technical pressure with a bearish signal. The company demonstrates strong fundamentals with consistent earnings beats, 77.28% gross margins, and 21.99% net income margins. Recent AI-driven growth initiatives show promise, with Agentforce and Data 360 ARR reaching $2.9 billion. However, the stock faces headwinds from broader software sector weakness and AI disruption concerns.
The investment case balances strong profitability and AI monetization potential against sector-wide pressures. With 76.5% analyst buy ratings and a $271.91 consensus target offering 19% upside, the stock appears fundamentally undervalued. Key risks include AI competition, macroeconomic sensitivity, and the recent 35% YTD decline testing investor patience despite solid financial performance.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
